BCHE and myasthenia gravis: At the time of enrolment, among all MG patients, 10 (14%) had thymoma, 9 (13%) used symptomatic monotherapy with cholinesterase inhibitors, and the majority (55%) additionally used oral corticosteroids and/or steroid-sparing immunosuppressive therapy (29%).